

Contents

Acknowledgments	v
Abstract	vii
List of Figures	xiii
List of Tables	xvi
Abbreviations	xviii
1 Introduction	1
1.1 The Fight against Cancer	1
1.2 Personalized Non Invasive Molecular Imaging to Improve Cancer Treatment	3
1.3 Outline and Scope of Thesis	6
2 Background and Review	8
2.1 Targeted Cancer Nanotherapies	8
2.2 Modulation of the Tumor Microenvironment to Enhance Drug Uptake	10
2.3 Imaging in Oncology	11
2.3.1 PET Basics	11
2.3.2 MRI Basics	14
2.3.3 Combining PET and MRI	20
2.3.4 Digital Whole-body Autoradiography	22
2.3.5 Imaging of Targeted Nanotherapy Uptake	24
2.3.6 Imaging of Targeted Nanotherapy Response	25

3	Development of Simultaneous PET/MRI Technology for Robust <i>In Vivo</i> Studies	26
3.1	Further Considerations of PET Insert Effects on <i>In Vivo</i> MRI Performance	26
3.1.1	Materials and Methods	26
3.1.2	Results	30
3.1.3	Discussion	36
3.2	A Robust Coregistration Method for <i>In Vivo</i> Studies Using a First Generation Simultaneous PET/MRI Scanner	39
3.2.1	Abstract	39
3.2.2	Introduction	40
3.2.3	Materials and Methods	42
3.2.4	Results	47
3.2.5	Discussion	52
3.2.6	Conclusions	55
3.2.7	Supplemental Data	56
3.3	Phantom Designs for Robust <i>In Vivo</i> Coregistration of Hybrid Imaging Systems: Comparison of Semiautomatic and Automatic Approaches	60
3.3.1	Introduction	60
3.3.2	Materials and Methods	61
3.3.3	Results	64
3.3.4	Discussion	65
3.4	Quantitative, Simultaneous PET/MRI for Intratumoral Imaging with a MR-compatible PET Scanner	67
3.4.1	Abstract	67
3.4.2	Introduction	68
3.4.3	Materials and Methods	70
3.4.4	Results	76
3.4.5	Discussion	82
3.4.6	Conclusions	87
3.4.7	Supplemental Data	87

3.5	Synchronization of PET/MRI Hardware	92
3.5.1	Materials and Methods	93
3.5.2	Discussion	93
3.6	MR Gradient Effects on the PET Insert	95
3.6.1	Materials and Methods	95
3.6.2	Results	96
3.6.3	Discussion	99
3.7	PET/MRI Informatics Considerations	103
3.7.1	Image Generation	103
3.7.2	Storage	103
3.7.3	Integration	103
3.7.4	Discussion	105
4	Serial Diffusion MRI to Monitor and Model Early Treatment Response to the Targeted Nanotherapy CRLX101	107
4.1	Abstract	107
4.2	Translational Relevance	108
4.3	Introduction	109
4.4	Materials and Methods	111
4.5	Results	114
4.6	Discussion	121
5	Imaging the Tumor Response to the Tumor-penetrating Peptide iRGD	126
5.1	Introduction	127
5.2	Materials and Methods	129
5.3	Results	137
5.4	Discussion	144
6	Summary and Future Work	153
6.1	Summary	153
6.2	Future Work	154

A	A Study of the Timing Properties of Position-sensitive Avalanche Photodiodes	159
B	Receptor-targeted Iron Oxide Nanoparticles for Molecular MR Imaging of Inflamed Atherosclerotic Plaques	185
C	Cooccurrence Matrices to Compare Multimodal Image Datasets: Further Considerations	199
D	Synchronous PET/MRI Software Code	208
E	MATLAB Implementation of a Unique Identifier for Multimodal Data Linkage	215
	Bibliography	217

List of Figures

1.1	Therapeutics targeting different hallmarks of cancer.	2
1.2	Five year cancer survival rates, 2001–2007.	4
2.1	Enhanced permeability and retention.	9
2.2	A basic pulsed gradient SE sequence for diffusion MRI imaging.	16
2.3	DCE-MRI can infer tissue vascular function.	19
2.4	Real-time paradigm for PET/MRI studies.	21
2.5	PSAPD-based MR-compatible PET insert.	22
3.1	B_0 comparisons with and without the PET insert for the spherical phantom.	31
3.2	B_0 fieldmaps in the presence of the PET insert for the spherical phantom.	32
3.3	B_0 fieldmaps in the presence of the PET insert for the cylindrical phantom.	33
3.4	B_0 comparisons with and without the PET insert for the cylindrical phantom.	34
3.5	Relative B_1 maps with and without the PET insert.	34
3.6	B_{1u} comparisons with and without the PET insert.	35
3.7	Dynamic MRI time traces with and without the PET insert.	37
3.8	Signal drift quantification with and without the PET insert.	38
3.9	PET/MR FOV alignment phantom.	44
3.10	PET/MR FOV alignment strategy registers other phantom sets robustly.	45
3.11	Different spatial resolution of the PET and MR images.	48
3.12	PET/MR images of tumor and heart.	50
3.13	PET/MR alignment using different geometries.	50
3.14	PET guided MRS assay of MC38.CEA tumor.	51
3.15	MR images with PET on/off.	57

3.16 Schematic of automatic phantom.	61
3.17 Semiautomatic and automatic alignment phantom renderings.	62
3.18 Automatic phantom rod delineation.	63
3.19 Automatic axial alignment of images.	64
3.20 Alignment phantom PET/MRI images.	65
3.21 Quantitative PET/MRI evaluation phantoms.	71
3.22 PET/MRI scanner accuracy and stability within an imaging session.	77
3.23 Linearity and stability of the PET/MRI scanner across multiple imaging sessions.	78
3.24 Multimodal imaging of radiotracer uptake in tumors.	79
3.25 Pixel-based similarity across PET/MRI scanner (frozen specimens), microPET and autoradiography images.	80
3.26 Structure-based similarity among PET/MRI scanner (frozen specimen), microPET and autoradiography images.	81
3.27 <i>In vivo</i> simultaneous diffusion MRI/radiolabeled antibody PET reveals phases of antibody uptake.	83
3.28 Cooccurrence matrix analysis of functional PET and MRI data offers insight into tumor antibody uptake.	84
3.29 Resolution differences between autoradiography and PET.	85
3.30 Linearity of PET/MR scanner, microPET R4 and autoradiography.	90
3.31 Scatter plot of simultaneous diffusion MRI and PET antibody measurements at two different times after injection of ^{64}Cu -labeled antibody.	91
3.32 Synchronous PET/MRI strategy.	92
3.33 Fast kinetics of small molecular agents necessitate synchronous PET/MRI.	94
3.34 MRI gradient effects on count rates.	96
3.35 MRI gradient effects on count rates for the PET insert.	97
3.36 MRI gradient effects on count rates for individual detectors.	98
3.37 Orientation of PET detector modules in MRI.	98
3.38 Energy spectra for different gradient conditions.	100
3.39 PET/MRI database setup.	104

4.1	Diffusion MRI is sensitive to early CRLX101 response.	115
4.2	Histogram analysis of diffusion MRI.	116
4.3	ADC changes over treatment week show efficacy of CRLX101.	117
4.4	Tumor volume size changes over treatment week.	118
4.5	A logistic model of tumor growth can be applied to ADC data.	119
4.6	Cellular proliferation rates for different treatment groups were calculated by applying ADC data to a logistic model of tumor growth.	120
4.7	Boxplots of cellular proliferation rates for different treatment groups.	120
4.8	Histological assessment of CRLX101 and CPT-11 response.	122
5.1	Study design for iRGD MRI.	131
5.2	AIF, tumor time curves and model fits from Magnevist injection.	134
5.3	Study design for Diffusion MRI/PET.	135
5.4	Heterogeneity of tumor CA uptake.	137
5.5	Vascular parametric maps for a single mouse over multiple days.	138
5.6	Mean percentage change from baseline, sorted by tumor K_{trans} value.	140
5.7	Mean percentage change from baseline, sorted by distance from tumor edge.	141
5.8	PET/MRI of radiolabelled-Herceptin uptake 1 hour post injection.	142
5.9	PET/ Diffusion MRI of radiolabelled-Herceptin uptake 3 and 20 hours post injection.	143
5.10	Immunofluorescence of antibody uptake with saline.	145
5.11	Immunofluorescence of antibody uptake with iRGD.	146
5.12	Distribution of antibody immunofluorescence with iRGD.	147
6.1	Simultaneous PET/MRI data can analyzed with image-based models.	156
C.1	Voxel-by-voxel comparisons between images with different spatial resolutions.	203
C.2	Correlation of baseline and blurred data at different FWHM.	204
C.3	Cooccurrence matrix comparison.	204
C.4	Concordance correlation coefficients for cooccurrence matrices compared to the control matrix.	205

List of Tables

2.1	Common positron-emitting isotopes	13
2.2	MRI contrast agents.	17
2.3	Comparison between PET and MRI	20
2.4	Current state of hybrid PET/MRI systems	23
3.1	Relative B_{1u} values with and without the PET insert	30
3.2	T_1 measurements with and without the PET insert	36
3.3	Centroid alignment error of phantoms using the PET/MR transformation scheme over multiple days.	49
3.4	Centroid alignment error as a function of location within the transaxial field of view.	51
3.5	^{18}F -FDG-PET-guided ^1H MRS.	52
3.6	Alignment displacements by different pulse sequences.	57
3.7	Alignment error using 2D transformation.	58
3.8	Alignment error using 3D transformation.	59
3.9	Alignment error comparison between automatic and semiautomatic alignment meth- ods.	65
3.10	Image similarity metrics used to compare PET image quality with autoradiography.	75
3.11	Count rate differences across different gradient conditions for individual detectors.	99
5.1	Vascular parameters for whole ROI	139
5.2	Percentage change of vascular parameters from baseline for whole ROI	139
5.3	Area under curve for whole ROI.	141
5.4	Percentage change of vascular parameters from baseline for whole ROI	141
5.5	Mean ADC values at 3 and 20 hours post iRGD treatment	144

5.6	Mean PET uptake values at 3 and 20 hours post iRGD treatment	144
5.7	Maximum PET uptake values at 3 and 20 hours post iRGD treatment	144

Abbreviations

^{18}F -FLT	^{18}F -3'-fluoro-3'-deoxy-1-thymidine
^{18}F -FDG	^{18}F -fluoro-deoxyglucose
ACR	Activity concentration recovery
ADC	Apparent diffusion coefficient
AIF	Arterial input function
ANOVA	Analysis of variance
APD	Avalanche photodiode
AUC	Area under the curve
BL	Burkitt's lymphoma
BOLD	Blood oxygen level dependent
CA	Contrast agent
CCC	Concordance correlation coefficients
CEA	Carcinoembryonic antigen
CoV	Coefficients of variation
CPT	Camptothecin
CT	Computer tomography
CWSSIM	Complex wavelet structural similarity index

DCE-MRI	Dynamic-contrast enhanced MRI
DOI	Depth of interaction
DOTA	1,4,7,10-tetraazacyclodecane-1,4,7,10-tetraacetic acid
DTPA	Diethylene triamine pentaacetic acid
DWBA	Digital whole-body autoradiography
EPI	Echo planar imaging
EPR	Enhanced permeability and retention
FA	Flip angle
FLASH	Fast low-angle shot MRI
fMRI	Functional MRI
FOV	Field of view
FWHM	Full width at half maximum
GUI	Graphical user interface
i.p.	Intraperitoneal
i.v.	Intravenous
ID	Inner diameter
LSO	Lutetium oxyorthosilicate
LV	Left ventricle
MAP	Maximum <i>a posteriori</i>
MR	Magnetic resonance
MRI	Magnetic resonance imaging

MRS	MR spectroscopy
NIM	Nuclear instrumentation module
NMR	Nuclear magnetic resonance
OD	Outer diameter
OSEM	Ordered-subset expectation maximization
PAF	Platelet activating factor
PCC	Pearson's correlation coefficients
PET	Positron emission tomography
PMT	Photomultiplier tubes
PSAPD	Position-sensitive avalanche photodiode
PSF	Point spread function
PSNR	Peak signal-to-noise ratio
QAR	Quantitative autoradiography
RARE	Rapid acquisition with relaxation enhancement
RF	Radiofrequency
RMSE	Root mean squared error
ROI	Region of interest
SD	Standard deviation
SE	Spin echo
SEM	Standard error of the mean
SiPM	Silicon photomultiplier

SNR	Signal to noise ratio
SPECT	Single-photon emission computer tomography
SSIM	Mean structural similarity index
TE	Echo time
TR	Repetition time
TRT	Treatment related toxicity
TTL	Transistor transistor logic
TUNEL	Terminal nucleotidyl transferase-mediated nick end labeling
VEGF	Vascular endothelial growth factor
VOI	Voxel of interest